CYTR: CytRx Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTR: CytRx Corporation

CYTR 0.0920

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: steve kammerer who wrote (11)	1/23/2005 9:56:38 AM
From: mopgcw	Read Replies (1) of 51

CytRx (CYTR-NNM) by Griffin Securities (1.21, Jan. 14) Strong new pipeline dynamics. ALS [Lou Gehrig's disease, or amyotrophic lateral sclerosis] program commencing Phase II. Potential for "orphan" drug designation and expedited Food and Drug Administration review. Arimoclomol showing potential for broader neurogenerative applicability. Potential of rapid entry into Phase II of iroxanadine for diabetic complications. Encouraging new data raises compound's cardiovascular profile. Small-molecule metabolic programs likely to provide partner news. Cutting-edge RNAi therapeutics programs provide exciting long-term value growth driver. Maintain Buy rating. Raising 12-month price target to 7.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next